ANI Pharmaceuticals, Inc. (ANIP)

ANI Pharmaceuticals Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Year Ending	TTM	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Cash & Equivalents	228.6	221.12	53.23	100.3	12.87	67.36
Short-Term Investments	9.66	0	0	0	0	0
Cash & Cash Equivalents	238.25	221.12	53.23	100.3	12.87	67.36
Cash Growth	251.63%	315.38%	-46.93%	679.51%	-80.90%	40.25%
Receivables	172.42	162.08	165.44	128.53	95.79	72.13
Inventory	113.84	111.2	105.36	81.69	60.8	48.16
Other Current Assets	16.05	25.42	20.23	11.26	0.86	0.04
Total Current Assets	540.56	519.82	344.26	321.78	170.32	187.7
Property, Plant & Equipment	48.53	44.59	43.25	52.67	41.27	40.55
Long-Term Investments	0	0	0	5	0	0
Goodwill and Intangibles	224.27	237.23	279.86	322.01	192.09	183.97
Other Long-Term Assets	101.18	102.78	92.72	70.14	57.51	44.58
Total Long-Term Assets	373.97	384.61	415.83	449.82	290.87	269.09
Total Assets	914.52	904.42	760.09	771.6	461.19	456.79
Accounts Payable	49.43	36.68	29.31	22.97	11.26	14.61
Deferred Revenue	0	0	0	0	0.08	0.45
Current Debt	0.85	0.85	0.85	0.85	13.24	9.94
Other Current Liabilities	86.61	107.94	69.28	63.72	53.98	36.68
Total Current Liabilities	136.89	145.48	99.44	87.54	78.57	61.68
Long-Term Debt	284.61	284.82	285.67	286.52	172.44	175.81
Other Long-Term Liabilities	16.22	16.53	36.44	38.8	14.48	6.51
Total Long-Term Liabilities	300.82	301.35	322.11	325.32	186.93	182.32
Total Liabilities	437.71	446.82	421.55	412.86	265.49	244
Total Debt	285.46	285.67	286.52	287.37	185.69	185.75
Debt Growth	-0.30%	-0.30%	-0.30%	54.76%	-0.03%	1.49%
Retained Earnings	-62.33	-80.13	-97.29	-47.77	-4.97	17.58
Comprehensive Income	9.41	8.86	12.17	-3.06	-11.44	-4.87
Shareholders' Equity	451.96	432.75	313.69	333.89	195.7	212.79
Net Cash / Debt	-47.21	-64.55	-233.29	-187.07	-172.82	-118.39
Net Cash Per Share	-2.43	-3.55	-14.35	-14.85	-14.44	-9.83
Working Capital	403.67	374.34	244.82	234.24	91.76	126.02
Book Value Per Share	23.27	23.79	19.29	26.51	16.36	17.67

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).